The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,001
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Mian, A., & Hill, B. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1889510 · Cited by 68
Self-citationShao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 67
Leclercq-Cohen, G., Steinhoff, N., Haegel, H., Marco, D. D., Bacac, M., & Klein, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083479 · Cited by 70
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Heard, A. D., Landmann, J. H., Hansen, A. R., Papadopolou, A., Hsu, Y.-S., Selli, M. E., Warrington, J. M., Lattin, J., Chang, J., Ha, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31035-7 · Cited by 69
Rejeski, K., Burchert, A., Iacoboni, G., Sesques, P., Fransecky, L. R., Bücklein, V., Trenker, C., Hernani, R., Naumann, R., Schäfer, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007776 · Cited by 67
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 68
Alexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 71
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 68
Levine, J. E., Grupp, S. A., Pulsipher, M. A., Dietz, A. C., Rives, S., Myers, G. D., August, K. J., Verneris, M. R., Buechner, J., Laetsch, T. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002287 · Cited by 68
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 68
Chimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 65
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 71
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia, A., Tarannum, M., Lérias, J. R., Piccinelli, S., Borrego, L. M., Maeurer, M. J., Romee, R., & Castillo-Martín, M. (2024) · Cells · doi:10.3390/cells13050451 · Cited by 69
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 68
Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 65
Hou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 64
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Anderson, L. D. (2021) · Future Oncology · doi:10.2217/fon-2021-1090 · Cited by 68
Rejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 64
Self-citationNagle, S. J., Murphree, C. R., Raess, P. W., Schachter, L. G., Chen, A., Hayes‐Lattin, B., Nemecek, E. R., & Maziarz, R. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26113 · Cited by 62
Liu, E., Ang, S., Kerbauy, L. N., Başar, R., Kaur, I., Kaplan, M., Li, L., Tong, Y., Daher, M., Ensley, E. L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626098 · Cited by 66
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J. G., & Kansagra, A. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00635-3 · Cited by 67
Sang, W., Wang, X., Geng, H., Li, T., Li, D., Zhang, B., Zhou, Y., Song, X., Sun, C., Yan, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858021 · Cited by 62
Velasco, R., Mussetti, A., Villagrán‐García, M., & Sureda, A. M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1144414 · Cited by 67
Scheubeck, G., Jiang, L., Hermine, O., Kluin‐Nelemans, H. C., Schmidt, C., Unterhalt, M., Rosenwald, A., Klapper, W., Evangelista, A., Ladetto, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01977-y · Cited by 62
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
Roex, G., Campillo-Davó, D., Flumens, D., Shaw, P. A. G., Krekelbergh, L., Reu, H. D., Berneman, Z. N., Lion, E., & Anguille, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03326-6 · Cited by 62
Bove, C., Arcangeli, S., Falcone, L., Camisa, B., Khoury, R. E., Greco, B. M., Lucia, A. D., Bergamini, A., Bondanza, A., Ciceri, F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005878 · Cited by 64
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Wang, Y., Buck, A., Piel, B. P., Zerefa, L., Murugan, N., Coherd, C. D., Miklosi, A. G., Johal, H., Bastos, R. N., Huang, K., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01952-w · Cited by 69
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62
Novel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 69
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
Raj, S. S., Fei, T., Fried, S., Ip, A., Fein, J. A., Leslie, L. A., Tomás, A. A., Leithner, D., Peled, J. U., Corona, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03532-x · Cited by 71
Stein-Merlob, A. F., Rothberg, M. V., Holman, P., & Yang, E. H. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01440-3 · Cited by 60
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 63
Peinelt, A., Bremm, M., Kreyenberg, H., Cappel, C., Banisharif-Dehkordi, J., Erben, S., Rettinger, E., Jarisch, A., Meisel, R., Schlegel, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830773 · Cited by 62
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
Todorović, Ž., Todorovic, D., Marković, V., Ladjevac, N., Zdravković, N., Djurdjevic, P. M., Arsenijević, N., Milovanović, M., Arsenijević, A., & Milovanović, J. (2022) · Current Oncology · doi:10.3390/curroncol29050293 · Cited by 62
Romain, G., Strati, P., Rezvan, A., Fathi, M., Bandey, I. N., Adolacion, J. R. T., Heeke, D., Liadi, I., Marques-Piubelli, M. L., Solis, L. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159402 · Cited by 62
Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
Schoutrop, E., Poiret, T., Serafi, I. E., Zhao, Y. H., He, R., Moter, A., Henriksson, J., Hassan, M., Magalhaes, I., & Mattsson, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005691 · Cited by 60
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 69
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine, J., Ruella, M., & Houot, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1559 · Cited by 61
Self-citationCheng, E. L., Cardle, I. I., Kacherovsky, N. A., Bansia, H., Wang, T., Zhou, Y., Raman, J., Yen, A., Gutierrez, D., Salipante, S. J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05349 · Cited by 60
Engineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 68
Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies
Chakraborty, R., Hill, B. T., Majeed, A., & Majhail, N. S. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.002 · Cited by 58
Self-citationMantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., Linton, K., & Dreyling, M. H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17419 · Cited by 59
CAR Treg: A new approach in the treatment of autoimmune diseases
Beheshti, S. A., Shamsasenjan, K., Ahmadi, M., & Abbasi, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108409 · Cited by 58
Wang, M. L., Jain, P., Zhao, S., Lee, H. J., Nastoupil, L. J., Fayad, L., Ok, C. Y., Kanagal‐Shamanna, R., Hill, H. A., Yao, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00638-0 · Cited by 56
Self-citationModulating tumor physical microenvironment for fueling CAR-T cell therapy
Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 59
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Zhang, Y., Zhou, W., Yang, J., Yang, J., & Wang, W. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00431-0 · Cited by 58
Kampouri, E., Ibrahimi, S. S., Xie, H., Wong, E. R., Hecht, J., Sekhon, M. K., Vo, A., Stevens‐Ayers, T., Green, D. J., Gauthier, J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad708 · Cited by 63
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
der Vreken, A. V., Vanderkerken, K., Bruyne, E. D., Veirman, K. D., Breckpot, K., & Menu, E. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00535-1 · Cited by 61
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Hermine, O., Jiang, L., Walewski, J. A., Bosly, A., Thiéblemont, C., Szymczyk, M., Pott, C., Salles, G., Feugier, P., Hübel, K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01780 · Cited by 57
Rejeski, K., Greco, R., Onida, F., Sánchez‐Ortega, I., Bonini, C., Sureda, A. M., Gribben, J. G., Yakoub‐Agha, I., & Subklewe, M. S. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000889 · Cited by 57
Overview of approved CAR-T products and utility in clinical practice
Bhaskar, S., Dholaria, B., Savani, B. N., Sengsayadeth, S. M., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.124277 · Cited by 67
Complications after CD19+ CAR T-Cell Therapy
Penack, O., & Koenecke, C. (2020) · Cancers · doi:10.3390/cancers12113445 · Cited by 59
Gutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 55
Self-citationHubbeling, H., Silverman, E. A., Michaud, L., Tomás, A. A., Shouval, R., Flynn, J. R., Devlin, S. M., Wijetunga, N. A., Tringale, K. R., Batlevi, C. L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.12.021 · Cited by 59
CAR T-Cell therapy for the management of mantle cell lymphoma
Huang, Z., Chavda, V. P., Bezbaruah, R., Dhamne, H., Yang, D., & Zhao, H.-B. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01755-5 · Cited by 64
Rejeski, K., dos Santos, D. M. C., Parker, N. H., Bücklein, V., Winkelmann, M., Jhaveri, K. S., Liu, L., Trinkner, P., Günther, S., Karschnia, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0487 · Cited by 56
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Self-citationKimmel, G. J., Locke, F. L., & Altrock, P. M. (2021) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2021.0229 · Cited by 68
Self-citationLuo, W., Li, C., Zhang, Y., Du, M., Kou, H., Lu, C., Mei, H., & Hu, Y. (2022) · BMC Cancer · doi:10.1186/s12885-021-09102-x · Cited by 57
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Gauthier, J., Gazeau, N., Hirayama, A. V. V., Hill, J. A., Wu, V., Cearley, A., Perkins, P., Kirk, A., Shadman, M. S., Chow, V. A., et al. (2022) · Blood · doi:10.1182/blood.2021014497 · Cited by 57
Frey, N. V. (2022) · Blood · doi:10.1182/blood.2021014892 · Cited by 57
Aharon, A., Horn, G., Bar-Lev, T. H., Yohay, E. Z., Waks, T., Levin, M., Deshet‐Unger, N., Avivi, I. M., & Levin, A. G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.192 · Cited by 55
Rejeski, K., Wang, Y., Albanyan, O., Munoz, J. L., Sesques, P., Iacoboni, G., López‐Corral, L., Ries, I., Bücklein, V., Mohty, R., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27056 · Cited by 55
Self-citationRecent updates on allogeneic CAR-T cells in hematological malignancies
Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S. S., & Sharifzadeh, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03479-y · Cited by 57
McCulloch, R., Lewis, D. J., Crosbie, N., Eyre, T. A., Bolam, S., Arasaretnam, A., Creasey, T., Goradia, H., McMillan, A., Dawi, S., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17363 · Cited by 54
Han, M. W., Jeong, S. Y., Suh, C. H., Park, H., Guenette, J. P., Huang, R. Y., Kim, K. W., & Yoon, D. H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1392831 · Cited by 57
Wang, M. L., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W. J., Wu, K. L., Bishton, M. J., Collins, G. P., Eliadis, P. E., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01188-x · Cited by 55
Self-citationSelf-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance
Muraoka, D., Harada, N., Shiku, H., & Akiyoshi, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.004 · Cited by 54
Zhao, H., Xue, S., Hussherr, M., Teixeira, A. P., & Fussenegger, M. (2022) · Science Advances · doi:10.1126/sciadv.abm4389 · Cited by 52
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 55
Potential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 54
Cardiovascular toxicity of immune therapies for cancer
Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 61
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Jain, P., Dreyling, M. H., Seymour, J. F., & Wang, M. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02287 · Cited by 53
Self-citationHadidi, S. A., Schinke, C., Thanendrarajan, S., Zangari, M., & van Rhee, F. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8161 · Cited by 51
Sudarsanam, H., Buhmann, R., & Henschler, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886637 · Cited by 54
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Patel, R. P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K. H., Chun, I., Angelos, M. G., Pajarillo, R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn6509 · Cited by 55
Self-citationEmerging therapies in mantle cell lymphoma
Hanel, W. G., & Epperla, N. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00914-1 · Cited by 50
Voorhees, T. J., Zhao, B., Oldan, J. D., Hucks, G., Khandani, A. H., Dittus, C. E., Smith, J. K., Morrison, J. K., Cheng, C. J. A., Ivanova, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005385 · Cited by 50
Schoeberl, F., Tiedt, S., Schmitt, A., Blumenberg, V., Karschnia, P., Burbano, V. G., Bücklein, V., Rejeski, K., Schmidt, C., Busch, G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006144 · Cited by 50
Borogovac, A., Keruakous, A. R., Bycko, M., Chakrabarty, J. H., Ibrahimi, S., Khawandanah, M. O., Selby, G. B., Yuen, C. H.-L., Schmidt, S. A., Autry, M. T., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01664-z · Cited by 50
Recognizing, defining, and managing CAR-T hematologic toxicities
Rejeski, K., Subklewe, M. S., & Locke, F. L. (2023) · Hematology · doi:10.1182/hematology.2023000472 · Cited by 52
Self-citationBajwa, A., Zhao, Q., Geer, M. J., Lin, C., Westholder, J. S., Maakaron, J. E., Ghosh, M., Frame, D. G., Galal, A., Tossey, J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013688 · Cited by 50
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 51
Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 51
Meng, J., Wu, X., Sun, Z., Xun, R., Liu, M., Hu, R., & Huang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698607 · Cited by 48
Cobb, D. A., de Rossi, J., Liu, L., An, E., & Lee, D. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003816 · Cited by 51
Self-citationNew Directions for Mantle Cell Lymphoma in 2022
Kumar, A. A., Eyre, T. A., Lewis, K. L., Thompson, M. C., & Cheah, C. Y. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349509 · Cited by 49
Alkhateeb, H. B., Mohty, R., Greipp, P. T., Bansal, R., Hathcock, M. A., Rosenthal, A. C., Murthy, H. S., Kharfan‐Dabaja, M. A., Villasboas, J. C., Bennani, N. N., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00707-4 · Cited by 49
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 49
Derigs, P., Schubert, M., Dreger, P., Schmitt, A., Yousefian, S., Haas, S. F., Röthemeier, C., Neuber, B., Hückelhoven‐Krauss, A., Brüggemann, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02392-7 · Cited by 48
In vivo generation of CAR T cells in the presence of human myeloid cells
Ho, N., Agarwal, S., Milani, M., Cantore, A., Buchholz, C. J., & Thalheimer, F. B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.004 · Cited by 48
Heß, G., Dreyling, M. H., Obéric, L., Giné, E., Zinzani, P. L., Linton, K., Vilmar, A. C., Jerkeman, M., Chen, J. M. H., Ohler, A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18519 · Cited by 48
Chimeric antigen receptor macrophages target and resorb amyloid plaques
Kim, A. B., Xiao, Q., Yan, P., Pan, Q., Pandey, G., Grathwohl, S., Gonzales, E. R., Xu, I., Cho, Y., Haecker, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175015 · Cited by 50
Targeting macrophages in cancer immunotherapy: Frontiers and challenges
Liu, Y., Tan, H., Dai, J., Lin, J., Zhao, K., Hu, H., & Zhong, C. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.043 · Cited by 55
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 55
Rusconi, C., Cheah, C. Y., Eyre, T. A., Tucker, D. L., Klener, P., Giné, E., Crucitti, L., Muzi, C., Iadecola, S., Infante, G., et al. (2022) · Blood · doi:10.1182/blood.2022015560 · Cited by 48
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 50
dos Santos, D. M. C., Rejeski, K., Winkelmann, M., Liu, L., Trinkner, P., Günther, S., Bücklein, V., Blumenberg, V., Schmidt, C., Kunz, W. G., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280189 · Cited by 46
Dizman, G. T., Aguado, J. M., & Fernández‐Ruiz, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2128762 · Cited by 47
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
